|
1
|
Hunger SP and Mullighan CG: Redefining ALL
classification: Toward detecting high-risk ALL and implementing
precision medicine. Blood. 125:3977–3987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
TeWinkel ML, Peiters R, Wind EJ, Bessems
JH and van den Heuvel-Eibrink MM: Management and treatment of
osteonecrosis in children and adolescents with acute lymphoblastic
leukemia. Haematologica. 99:430–436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nair M, Kusumakumary P and Nair PS: Rare
presentation of pediatric acute promyelocytic leukemia as multiple
lytic bone lesions: Case report and review of the literature. J
Cancer Res Ther. 10:381–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chalandon Y, Thomas X, Hayette S, Cayuela
JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre
S, et al: Group for Research on Adult Acute Lymphoblastic Leukemia
(GRAALL): Randomized study of reduced-intensity chemotherapy
combined with imatinib in adults with Ph-positive acute
lymphoblastic leukemia. Blood. 125:3711–3719. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ross DM, Branford S, Moore S and Hughes
TP: Limited clinical value of regular bone marrow cytogenetic
analysis in imatinib-treated chronic phase CML patients monitored
by RQ-PCR for BCR-ABL. Leukemia. 20:664–670. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matutes E, Pickl WF, Van't Veer M, Morilla
R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S,
Bene MC, et al: Mixed-phenotype acute leukemia: Clinical and
laboratory features and outcome in 100 patients defined according
to the WHO 2008 classification. Blood. 117:3163–3171. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faderl S, O'Brien S, Pui CH, Stock W,
Wetzler M, Hoelzer D and Kantarjian HM: Adult acute lymphoblastic
leukemia: Concepts and strategies. Cancer. 116:1165–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leblicq C, Laverdière C, Decarie JC,
Delisle JF, Isler MH, Moghrabi A, Chabot G and Alos N:
Effectiveness of pamidronate as treatment of symptomatic
osteonecrosis occurring in children treated for acute lymphoblastic
leukemia. Pediatr Blood Cancer. 60:741–747. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Atas A, Cakmak A, Soran M, Soker M and
Varma M: Severe osteoporosis and high level TSH in a child before
the diagnosis of acute lymphoblastic leukemia. J Pediat Hematol
Oncol. 31:588–591. 2009. View Article : Google Scholar
|
|
10
|
Bertuna G, Famà P, Lo Nigro L,
Russo-Mancuso G and Di Cataldo A: Marked osteoporosis and
spontaneous vertebral fractures in children: Don't forget, it could
be leukemia. Med Pediatr Oncol. 41:450–451. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hafiz MG and Islam A: Extensive skeletal
lesions in childhood acute lymphoblastic leukemia. Mymensingh Med
J. 18:88–94. 2009.PubMed/NCBI
|
|
12
|
Hafiz MG, Islam A and Siddique R: Back
pain and vertebral compression: An unusual presentation of
childhood acute lymphoblastic leukemia. Mymensingh Med J.
19:130–136. 2010.PubMed/NCBI
|
|
13
|
Kim DH and Vaccaro AR: Osteoporotic
compression fractures of the spine; current options and
considerations for treatment. Spine J. 6:479–487. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaloostian PE, Zadnik PL, Etame AB,
Vrionis FD, Gokaslan ZL and Sciubba DM: Surgical management of
primary and metastatic spinal tumors. Cancer Control. 21:133–139.
2014.PubMed/NCBI
|
|
15
|
Shah NR, Landi DB, Kreissman SG, Kulbachi
E and Moran C: Presentation and outcomes for children with bone
marrow necrosis and acute lymphoblastic leukemia: A literature
review. J Pediatr Hematol Oncol. 33:e316–e319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Usuki K, Tojo A, Maeda Y, Kobayashi Y,
Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura
K, et al: Efficacy and safety of nilotinib in Japanese patients
with imatinib-resistant or -intolerant Ph+ CML or
relapsed/refractory Ph+ ALL: A 36-month analysis of a phase I and
II study. Int J Hematol. 95:409–419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas DA, Faderl S, Cortes J, O'Brien S,
Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M,
Jeha S, et al: Treatment of Philadelphia chromosome-positive acute
lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood.
103:4396–4407. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mizuta S, Matsuo K, Maeda T, Yujiri T,
Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, et al:
Prognostic factors influencing clinical outcome of allogeneic
hematopoietic stem cell transplantation following imatinib-based
therapy in BCR-ABL-positive ALL. Blood Cancer J. 2:e722012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ohno R: Changing paradigm of the treatment
of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Curr Hematol Malig R. 5:213–221. 2010. View Article : Google Scholar
|
|
20
|
Philippe R, Marie M, Françoise H, et al:
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line
Treatment in Patients with De Novo Philadelphia Positive ALL Aged
55 and Over: Final Results of the EWALL-Ph-01 Study. Blood (ASH
Annual Meeting Abstracts). 120:6122012.
|
|
21
|
Mizuta S, Matsuo K, Yagasaki F, et al:
Pre-transplant imatinib-based therapy improves the outcome of
allogeneic hematopoietic stem cell transplantation for
BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 25:41–47.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heike P, Sylvia W, Binckebanck A, et al:
Imatinib (IM) and interferon-alpha (IFN-α) maintenance therapy is
associated with long-term DFS in a subset of elderly patients with
Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood
(ASH Annual Meeting Abstracts). 120:15032012.
|
